Key Points
- Urogen Pharma CFO Chris Degnan sold 2,202 shares at an average price of $36.69, generating approximately $80,791. After the transaction, he retained 4,561 shares, a 32.56% reduction in his direct ownership.
- URGN opened at $36.83, with a market capitalization of approximately $1.80 billion. The stock has traded between $15.86 and $50.81 over the past year.
- Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $52.38, while institutional investors own 91.29% of the company’s shares.
Urogen Pharma (NASDAQ:URGN - Get Free Report) CFO Chris Degnan sold 2,202 shares of the business's stock in a transaction on Thursday, October 8th. The shares were sold at an average price of $36.69, for a total transaction of $80,791.38. Following the sale, the chief financial officer directly owned 4,561 shares in the company, valued at approximately $167,343.09. This trade represents a 32.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.
Urogen Pharma Stock Down 0.4%
URGN opened at $36.83 on Friday. The firm has a market capitalization of $1.80 billion, a P/E ratio of -18.60 and a beta of 1.57. The stock has a fifty day moving average of $43.82 and a 200-day moving average of $34.59. Urogen Pharma has a 12-month low of $15.86 and a 12-month high of $50.81.
Urogen Pharma (NASDAQ:URGN - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.02). The firm had revenue of $72.46 million during the quarter, compared to analyst estimates of $63.55 million. On average, analysts expect that Urogen Pharma will post -0.20 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of research firms have recently issued reports on URGN. Jefferies Financial Group reissued a "buy" rating and issued a $56.00 price target on shares of Urogen Pharma in a research report on Thursday, September 10th. Guggenheim boosted their price objective on shares of Urogen Pharma from $42.00 to $58.00 and gave the company a "buy" rating in a research report on Thursday, August 6th. UBS Group reiterated a "buy" rating on shares of Urogen Pharma in a research note on Thursday, July 9th. Oppenheimer increased their target price on shares of Urogen Pharma from $40.00 to $50.00 and gave the stock an "outperform" rating in a research report on Thursday, July 16th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Urogen Pharma in a research note on Friday, July 17th. Eight investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, Urogen Pharma has a consensus rating of "Moderate Buy" and a consensus price target of $52.38.
Get Our Latest Stock Analysis on Urogen Pharma
Institutional Investors Weigh In On Urogen Pharma
A number of hedge funds and other institutional investors have recently made changes to their positions in URGN. Persistent Asset Partners Ltd bought a new position in Urogen Pharma during the second quarter valued at approximately $66,000. Quantbot Technologies LP bought a new stake in Urogen Pharma in the second quarter worth approximately $78,000. Glenmede Trust Co. NA acquired a new position in shares of Urogen Pharma during the 1st quarter worth $189,000. The Manufacturers Life Insurance Company acquired a new position in shares of Urogen Pharma during the 2nd quarter worth $412,000. Finally, Squarepoint Ops LLC bought a new position in shares of Urogen Pharma during the 2nd quarter valued at $431,000. 91.29% of the stock is owned by hedge funds and other institutional investors.
About Urogen Pharma
(
Get Free Report)
UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing therapies for cancers of the urinary tract. The company's platform is based on RTGel, a proprietary reverse-thermal hydrogel designed to retain medicines in the urinary tract and provide localized treatment while limiting systemic exposure.
UroGen's lead commercial product is JELMYTO (mitomycin), a gel-based therapy approved by the U.S. Food and Drug Administration for the primary chemoablation of low-grade upper tract urothelial cancer in adults.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
